Top 5 Drugs of 2018 in the USA
Copaxone (Glatiramer acetate), Teva Pharmaceutical Industries
Revenue from the drug sales in the US in 2016: $3.479 billion. Patent expiration date: expected in 2017. Copaxone (Glatiramer Acetate), intended for the treatment of multiple sclerosis, was first approved by the Food and Drug Administration (FDA) of the United States in 1996. Several years ago, Teva Pharmaceutical Industries faced a patent problem. However, it is expected that this form of drug release in 2017 may face competition from generics’ part, which could potentially lead to a reduction in drug sales in the future.
Cialis (tadalafil), Eli Lilly
Income from sales of the drug in the United States in 2018: $1,469 billion. Patent expiration date: November 2018. According to the Evaluate analytical company, it is expected that immediately 2 blockbusters of the Eli Lilly company will lose patent protection in the USA in 2018 – Cialis (tadalafil) and Alimta (pemetrexed), and also Strattera (atomoxetine) and Effient (prasugrel) which are less profitable for the company than the first 2 drugs.
In 2016, sales of the drug Cialis (tadalafil) in the United States, intended for the treatment of erectile dysfunction, amounted to $1.489 billion. However, it is expected that entering the generic market will bring significant revenue. According to analysts of the company Evaluate, the sales of Cialis (tadalafil) in the USA in 2022 will be only $55 million. It should be noted that this originator has already made a significant contribution to the income from the sales of Eli Lilly during its marketing in the amount of more than $17 billion. The company is struggling to extend the term of patent protection for this drug in the United States by expanding its scope of use in pediatrics. And this is not surprising, because, according to the Evaluate company, Cialis (tadalafil) sales in terms of money make up about 14% of Eli Lilly’s worldwide sales revenue and 16% in the United States.
Viagra (Sildenafil), Pfizer
Revenue from sales of the drug in the United States in 2018: $ 1.148 billion. Patent expiration date: December 2018
Viagra (Sildenafil), a well-known drug for the treatment of erectile dysfunction, was approved by the FDA in 1998. For almost two decades since the drug was approved, Pfizer has done a lot to market this brand and promote it among specialists. As a result, this innovative drug achieved blockbuster status, and its sales in the United States in 2018, according to FiercePharma, amounted to $1.148 billion.
Velcade (bortezomib), Takeda
Revenue from sales of the drug in the USA in 2018: $1.13 billion. Patent expiration date: November 2018. In 2015, a US federal court ruled that a patent that granted exclusivity to Velcade (bortezomib) until 2022 is inactive. In this regard, in the near future, this anticancer drug is likely to face competition from generics. Thus, «Evaluate» predict that sales of Velcade (bortezomib) in the United States by 2022 will be $187 million. In order to compensate for the lack associated with the loss of exclusivity on Velcade (bortezomib), Takeda has made significant efforts to market new products globally.
Sustiva (efavirenz), Bristol-Myers Squibb
Revenue from sales of the drug in the United States in 2018: $ 901 million. Patent expiration date: December 2018. Sustiva (efavirenz) is an antiviral drug for treating HIV infection. At the end of 2016, its sales in the United States amounted to $901 million. In turn, global sales revenue reached $1.065 billion. Sustiva sales revenue in the United States is less than 1/20 of the company’s sales revenue. Patent protection for the formula of this means ended in 2013, and the exclusivity of the treatment method is lost in 2017. Previously, Bristol-Myers Squibb extended the term of patent protection to Sustiva (efavirenz) for up to 6 months by expanding its scope in the children’s age group. To offset the risks associated with losing exclusivity on Sustiva (efavirenz), Bristol-Myers Squibb is making efforts to market new brands, including the antitumor drug Opdivo (nivolumab).